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Background: Anticoagulation (AC) adherence after acute pulmonary embolism (PE) is vital to prevent mortality
and future recurrence of venous thromboembolism (VTE). We aimed to analyze factors affecting AC adherence
after acute PE.
Methods: Consecutive adult patients with CT angiography or V/Q scan confirmed acute PE were included in a
single-center retrospective study from April 2016 to May 2020. Adherence data, including AC refill dates, were
collected from pharmacies, and adherence measures including Continuous Measure of Medication Acquisition
(CMA), Proportion of Days Covered (PDC), and Optimal Medication Adherence (OMA) were calculated per
standardized formulas. Univariable and multivariable linear and logistic regression was used to analyze different
variables affecting AC adherence.
Results: A total of 118 out of 144 patients had sufficient follow-up data to measure adherence and were included
in the final analysis. Mean age was 60 ± 15 years, with 64 (54.2%) women; 70 (59.3%) White, 26 (22%) African
American, 13 (11%) Hispanic; 58 (49.2%) patients had private insurance, 48 (40.7%) Medicare, 11 (9.3%)
Medicaid. Type of AC comprised of 57 (48.3%) apixaban, 17 (14.4%) rivaroxaban, 8 (6.8%) warfarin, 6 (5.1%)
enoxaparin, and 30 (25.4%) patients with changing AC. In univariable regression, African American and
Medicaid-insured patients had significantly lower adherence, while advancing age, apixaban usage, and 30-day
follow-up clinic visit showed a higher adherence. However, in multivariable regression, African American race
(PDC -0.135, p = 0.006, CI (− 0.231, − 0.040) | OMA Adjusted OR 0.166, p = 0.030, CI (0.033, 0.837)) and other
non-White, non-Hispanic races (PDC -0.314, p = 0.009, CI (− 0.548, − 0.080)) were associated with lower AC
adherence.
Conclusion: In our study, African American and other minority race patients showed lower AC adherence after
hospital admission for acute PE. Further studies are needed to address underlying contributors and improve
adherence in this population.

1. Introduction
Approximately 900,000 people in the U.S. are affected by pulmonary
embolism (PE) annually, with 150,000 to 250,000 PE-related hospital
izations [1]. Up to 100,000 will die annually from PE-related

complications [1]. Ten to thirty percent of people will die within one
month of diagnosis and one-third will have a recurrence within 10 years
[2]. Complications associated with PE include hypotension, hypoxemia,
cardiac dysrhythmias, and sudden cardiac death, depending on the
severity of PE [3]. In addition to the physiologic complications, PE also
leads to decreased quality of life correlating with PE severity [4].
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institutional review board approved the study.
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2.1. Study population

Anticoagulation
Continuous Measure of Medication Acquisition
Optimal Medication Adherence
Proportion of Days Covered
Pulmonary Embolism
Pulmonary Embolism Response Team
Venous Thromboembolism

Consecutive adult (>18 years) patients hospitalized with a primary
or secondary acute PE diagnosis as confirmed by CT angiography or V/Q
scan were included in the initial screen. Exclusion criteria included
patients for whom anticoagulation was contraindicated, patients with
clinically suspected PE without any imaging confirmation, patients with
a low-risk PE who were discharged directly from the emergency
department without PERT activation or hospitalization, and patients
who died during the index hospitalization. Of 144 consecutive patients
initially enrolled in the study, 26 (22%) were subsequently excluded
(Fig. 1).

Anticoagulation medications are the cornerstone of PE management
[5]. The standard duration of AC is three to six months, but extended AC
is recommended for unprovoked PE or those patients with high risk of
recurrence [6]. Uninterrupted anticoagulation is critically important as
gaps in therapy can lead to increased complications and even death.
Prior cohort studies have shown a significant increase in mortality and
risk of recurrent venous thromboembolism (VTE) when AC is not strictly
adhered to [7]. Non-adherence has also been associated with increased
healthcare expenditure both in the inpatient and outpatient settings [8].
There is a potential role for implementation of a Pulmonary Embo
lism Response Team (PERT) in increasing medication adherence. Over
38% of patients diagnosed with VTE are lost to follow-up [9]. Estab
lishing a pathway for the targeted transition of care for PE and atten
dance at a post-PE clinic may help improve adherence. Other studies
have also shown increased DOAC use post PERT implementation and
with patient education [10].
Despite the increased risk of complications when treatment strate
gies for PE are not followed as prescribed, medication non-adherence is
an ongoing challenge. There is a scarcity of data assessing factors
contributing to medication non-adherence, leaving the physician and
care team poorly equipped to address this issue. Our study aims to
identify factors that may predict poor anticoagulation adherence to
better understand the barriers these patients face and prevent adverse
PE-related events.

2.2. Data collection
Data collection included the type of anticoagulation prescribed on
discharge, anticoagulation refill dates from the patient’s pharmacy, in
surance type, completion of 30-day follow-up clinic visit, whether the
patient received an in-hospital education package regarding the diag
nosis and treatment of PE, as well as demographic data (age, gender, and
race). Data was collected through retrospective chart review using
electronic medical record and stored using REDCap (Research Electronic
Data Capture: Vanderbilt University, TN) web-based database. The refill
dates were obtained by calling patient pharmacies. Patients hospitalized
long enough to be seen by a member of the PERT team were also given
an educational package containing images and a summary of PE
symptomatology, diagnosis, and treatment in patient-friendly language,
as well as links for further reading, before discharge (Appendix 1).
2.3. Outcome parameters
The primary outcome of interest was anticoagulation adherence.
This was measured objectively in three different ways: (i) Continuous
Measure of Medication Acquisition (CMA), (ii) Proportion of Days
Covered (PDC), and (iii) Optimal Medication Adherence (OMA). The
CMA is an extension of the Medication Possession Ratio (MPR), one of
the most common methods of assessing pharmaceutical adherence [11].
The MPR is calculated as the sum of days of a particular medication filled
in a given refill period divided by the number of days in that period.
When this ratio is assessed over several refill intervals, it is referred to as

2. Methods
This was a single-center retrospective study performed at a tertiary
care urban teaching hospital from April 2016 to May 2020. The

Patients
Screened
(N=144)

Patients
Studied
(N=118)

Apixaban
(n=57)

Rivaroxaban
(n=17)

Warfarin
(n=8)

Enoxaparin
(n=6)

Switching of
Anticoagulation
(n=30)

Fig. 1. Flowchart of patient selection and anticoagulation on discharge.
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the CMA, as shown in Equation 1 [11].
Equation 1.
CMA =

Table 1
Baseline demographics.
Age — yrs (mean ± SD)

Number of days of medication supplied within refill periods
Number of days in refill periods

Gender — no. (%)
Male
Female
Race
White
African American
Hispanic
Other (minority)
Missing
Anticoagulant Type — no. (%)
Warfarin
Apixaban
Rivaroxaban
Enoxaparin
vChanging/Mixed
30-Day Follow-Up Visit — no. (%)
Yes
No
Insurance Type — no. (%)
Private
Medicare
Medicaid
Self-pay
In-Hospital Education — no. (%)
Yes
No

The major drawback to this method is that when a medication is
refilled before the end of an initial refill period, the periods overlap, and
the total number of days the prescription is filled becomes greater than
the total number of days in the initial refill period, resulting in a CMA
>1, or adherence >100%.
The PDC is defined as the ratio of the number of days of drug on-hand
to the total number of days in the respective time period, as shown in
Equation 2 [11].
Equation 2.
PDC =

Number of days with medication on hand
Number of days in period

In recent years the PDC has gained popularity as a more accurate
gauge of medication adherence. Unlike the CMA, there is no potential
overlap of days covered, and the maximum value for the PDC is 1,
indicating 100% adherence [11]. However, accurately gauging whether
a patient is covered during a given interval can at times be challenging
and lead to a more technically difficult computation to perform
compared to the MPR or CMA [12]. The OMA is a binary variable. Pa
tients with CMA or PDC >0.8 were classified as having OMA, and those
below that threshold did not have OMA. As the OMA relies in part on the
CMA, the OMA can also be misleadingly optimistic when a medication is
filled early in a given refill period.

60 ± 15
54 (45.8%)
64 (54.2%)
70 (59.3%)
26 (22.0%)
13 (11.0%)
3 (2.5%)
6 (5.0%)
8 (6.8%)
57 (48.3%)
17 (14.4%)
6 (5.1%)
30 (25.4%)
110 (93.2%)
8 (6.8%)
58 (49.2%)
48 (40.7%)
11 (9.3%)
1 (0.8%)
84 (71.2%)
34 (28.8%)

patients achieved more than 80% adherence or OMA.
In univariable analysis, increasing age (PDC coeff. = 0.003, p =
0.018, CI (0.001, 0.005) | OMA Unadjusted OR = 1.034, p = 0.027, CI
(1.004, 1.064)), treatment with apixaban (PDC coeff. = 0.160, p =
0.033, CI (0.013, 0.307) | OMA Unadjusted OR = 5.000, p = 0.058, CI
(0.948, 26.378)), and attending 30-day follow-up in clinic (PDC coeff. =
0.183, p = 0.012, CI (0.041, 0.324)) were statistically significant for
higher adherence. Conversely, African American race (PDC coeff. =
− 0.174, p < 0.001, CI (− 0.258, − 0.091) | OMA Unadjusted OR = 0.130,
p = 0.002, CI (0.036, 0.465)), other minority race (PDC coeff. = − 0.290,
p = 0.014, CI (− 0.519, − 0.061)), and Medicaid-insured patients (PDC
coeff. = − 0.270, p < 0.001, CI (− 0.391, − 0.148) | OMA Unadjusted OR
= 0.080, p = 0.001, CI (0.019, 0.345)) had significantly lower adher
ence. However, when adjusted for confounding variables in multivari
able regression, African American race (PDC coeff. = − 135%, p = 0.006,
CI (− 0.231, − 0.040) | OMA Adjusted OR = 0.166, p = 0.030, CI (0.033,
0.837)) and other non-White, non-Hispanic races (PDC coeff. = − 0.314,
p = 0.009, CI (− 0.548, − 0.080)) independently had lower anti
coagulation adherence when compared to their White counterparts as
measured by PDC (Tables 2 and 3, Fig. 2). Appendix 3 shows AC
adherence measured using CMA.

2.4. Statistical analysis
Categorical variables are presented as numbers (%) and continuous
variables were listed as mean ± standard deviation (SD). Continuous
variables were tested for normality using standard methods. Assump
tions of regression analysis were evaluated and met for the given data.
Univariable and multivariable linear and logistic models were used to
determine significant associations between different measures of
adherence (CMA, PDC, and OMA) with age, gender, race, type of anti
coagulant, type of insurance, and patients with 30-day follow-up, using
STATA15 (StataCorp LLC, TX). Variables with proven significance in the
univariable model were included in the multivariable model. Additional
variables were chosen as medication adherence is often influenced by
appropriate patient understanding, insurance coverage, and anti
coagulation dosing regimens [13].
3. Results
Of the 144 patients initially enrolled in the study, 118 (82%) filled
their medication more than once and therefore had sufficient data to
calculate the CMA, PDC, and OMA. Table 1 shows the demographics of
the included 118 patients. The mean age was 60 ± 15 years, with 64
(54.2%) women and 54 (45.8%) men. Of all patients included in the
study, there were 70 (59.3%) White, 26 (22%) African American, 13
(11%) Hispanic, 3 (2.5%) other minority races, and 6 (5%) unknown
ethnicities. Fifty-eight (49.2%) patients had private insurance, 48
(40.7%) Medicare, 11 (9.3%) Medicaid, and 1 (0.8%) self-pay. Patients
were prescribed one of the several forms of AC based on patient-provider
preference, age, insurance, and underlying co-morbidities: 57 (48.3%)
patients took apixaban, 17 (14.4%) rivaroxaban, 8 (6.8%) warfarin, and
6 (5.1%) enoxaparin. The remaining 30 (25.4%) patients switched from
one form of AC to another during the study due to cost, availability, drug
failure, or patient-provider preference.
Of the 118 patients analyzed, 58 (49.2%) had a PDC of 1, and 56
(47.4%) had a CMA of at least 1, indicating 100% adherence. The PDC
had a range of 0.081–1 and a mean of 0.88 ± 0.20 (SD). The CMA had a
range of 0.081–12.85 and mean of 1.08 ± 1.27. Ninety-four (79.7%)

4. Discussion
Anticoagulation for a minimum of three months is the standard
therapy for patients with reversible, provoked first incidence of acute PE
who otherwise do not have contraindications for anticoagulation. Nonadherence with anticoagulation can increase rates of complications from
VTE, including mortality and recurrence [7]. Prior studies in atrial
fibrillation — another clinical entity which requires regular use of AC to
prevent systemic thromboembolism — identified factors that predict
anticoagulation non-adherence, including minority race, unmarried
status, physical inactivity, alcohol use, self-reported poor physical or
mental health, or sleep quality, inadequate health literacy, low-dose
aspirin use, diabetes, forgetfulness, and medication concerns [14,15].
Conversely, age 65–84, presence of hypertension, behavioral factors
such as routine and external intervention, and medication knowledge
have been associated with higher levels of adherence [14,15]. Our study
evaluated several factors that may impact anticoagulation adherence,
3
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Table 2
Predictors of Anticoagulation Compliance measured as Proportion of Days
Covered (PDC).
Univariable
Regression

Age
Female
Race
White
African
American
Hispanic
Others
Anticoagulant
Warfarin
Apixaban
Rivaroxaban
Enoxaparin
Changing/
Mixed
30-Day Follow-Up
Visit
Insurance
Private
Medicare
Medicaid
Self-pay
In-Hospital
Education

Multivariable
Regression

Coefficient (95%
CI)

p value

Coefficient (95%
CI)

p
value

0.003 (0.001,
0.005)
− 0.003 (− 0.076,
0.071)

0.018

0.002 (− 0.002,
0.006)
–

0.337

Reference
− 0.174 (− 0.258,
− 0.091)
− 0.005 (− 0.111,
0.100)
− 0.290 (− 0.519,
− 0.061)
Reference
0.160 (0.013,
0.307)
0.140 (− 0.027,
0.307)
0.096 (− 0.114,
0.306)
0.062 (− 0.093,
0.217)
0.183 (0.041,
0.324)
Reference
− 0.038 (− 0.111,
0.034)
− 0.270 (− 0.391,
− 0.148)
0.076 (− 0.298,
0.449)
0.049 (− 0.032,
0.129)

Table 3
Predictors of Anticoagulation Compliance measured as Optimal Medication
Adherence (OMA).

0.942

<0.001
0.924
0.014

0.033
0.099
0.368
0.427
0.012

0.296
<0.001
0.689
0.233

Reference
− 0.135 (− 0.231,
− 0.040)
0.001 (− 0.116,
0.118)
− 0.314 (− 0.548,
− 0.080)
Reference
0.018 (− 0.139,
0.176)
− 0.032 (− 0.203,
0.138)
− 0.114 (− 0.335,
0.107)
− 0.056 (− 0.222,
0.110)
− 0.061 (− 0.253,
0.131)
Reference
− 0.058 (− 0.151,
0.036)
− 0.049 (− 0.224,
0.126)
0.097 (− 0.238,
0.433)
–

Age
Female
Race
White
African American

–

Hispanic

0.006

Others

0.987

Anticoagulant
Warfarin
Apixaban

0.009

Rivaroxaban

0.820

Enoxaparin

0.706

Changing/Mixed

0.306

30-Day Follow-Up
Visit
Insurance
Private
Medicare

0.502
0.530

Medicaid

0.221

Self-pay
In-Hospital
Education

0.580
0.564

a

–

Unadjusted OR
(95% CI)

p
value

Adjusted OR
(95% CI)

p
value

1.034 (1.004,
1.064)
0.984 (0.400,
2.421)

0.027

1.044 (0.977,
1.116)
–

0.201

Reference
0.130 (0.036,
0.465)
1.063 (0.112,
10.123)
0.106 (0.006,
1.975)
Reference
5.000 (0.948,
26.378)
2.800 (0.419,
18.689)
1.200 (0.130,
11.052)
1.200 (0.237,
6.065)
2.514 (0.556,
11.363)
Reference
0.532 (0.185,
1.526)
0.080 (0.019,
0.345)

0.972

0.002
0.957
0.133

0.058
0.288
0.872
0.825
0.231

0.241
0.001

a

a

0.774 (0.278,
2.156)

0.624

Reference
0.166 (.033,
0.837)
1.231 (0.093,
16.370)
0.047 (0.002,
1.235)
Reference
2.221 (0.115,
42.743)
1.026 (0.049,
21.578)
0.109 (0.002,
4.842)
0.810 (0.046,
14.326)
–

Reference
0.199 (0.029,
1.377)
0.261 (0.015,
4.400)

–

0.030
0.875
0.067

0.597
0.987
0.252
0.886
–

0.102
0.351

a

a

–

–

Insufficient data.

non-adherence persists in African American patients at a significantly
higher rate than White patients.20,21These findings could be due to
additional factors that are difficult to measure but potentially function
as a barrier to adherence, including greater concern for harmful medi
cation side effects, fear of dependency, reluctance to add medication to
existing regimens, and mistrust and skepticism of the medical system
[20–24].
One avenue for mitigating these concerns may be through in-hospital
education, an intervention that was explored in our study. Eighty-four
(71.2%) of the 118 patients were in the hospital long enough to be
given a newly developed information packet with patient-friendly lan
guage and images describing types of blood clots, signs and symptoms of
PE, causes of PE, severity of PE, tests for diagnosis, treatments (medi
cations and procedures), safety information, and links for further
reading. PERT physicians reviewed images of each patient’s PE with
them, in addition to discussing various treatment modalities as per the
standard protocol. These patients were also given a questionnaire before
and after receiving the information packet to evaluate whether their
understanding of PE changed after reading it (Appendix 2). Analysis in
this study showed no significant differences in AC adherence with pa
tients who received the in-hospital education versus those who did not.
However, other studies have shown that patient education may lead to a
significant increase in patient adherence, at least in the short term [25,
26]. Difference in outcome could be attributed to the low power of our
study (due to small sample size) or types of education material provided
(packet versus questionnaire versus one-on-one counseling versus
ongoing periodic reminders and check-ins). Future avenues of investi
gation may be able to explore whether various types of patient education
have a differential impact on disease comprehension and whether pa
tient education specifically targeting factors associated with poor
adherence yields improvements in adherence among African American

including age, gender, race, type of anticoagulant, 30-day clinic
follow-up visit, type of insurance, and the presence of in-hospital
education.
In univariable analysis, increasing age, use of apixaban, and atten
dance at a 30-day follow-up clinic visit were statistically significant for
higher PDC, while African American race and Medicaid-insured patients
had significantly lower PDC. In multivariable regression, African
American race resulted in lower PDC and OMA when compared to White
race. Patients of other minority races also had a significantly lower PDC.
These findings are consistent with prior studies exploring the impact of
race on medication adherence across different types of medications and
diseases, such as hypertension, dyslipidemia, and diabetes mellitus
[16–19]. Additionally, only those adhering to a self-pay insurance model
in our study maintained higher CMA. However, after carefully reviewing
the underlying dataset, only one patient of the 118 analyzed was cate
gorized into a self-pay insurance model. That patient had a corre
sponding CMA of 7.5, largely skewing the data and perceived
significance of this finding in relation to true adherence. If anything, this
finding serves as a further reminder of the shortcomings of CMA as a
consistently accurate means of assessing adherence.
The next step in understanding the relationship between race and
medication adherence would be to identify factors not measured in our
dataset, which may be associated with race and may be driving reduced
anticoagulation adherence and thus providing opportunities for
improvement. These factors might include socioeconomic status, health
literacy, physical and financial access to healthcare, mental health, and
social support, among others. Several studies, however, have found that
even after adjusting for underlying factors such as income, insurance
coverage, health literacy, depression, and social support, medication
4
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Fig. 2. Forest plot showing Predictors of Anticoagulation Adherence measured using Proportion of Days Covered (PDC) in a Multivariable Linear Regression Model
(Logarithmic Scale).

patients.
The major strength of our study is that it includes a broad range of
anticoagulant types, insurance types, and patient demographics,
whereas prior studies have primarily focused on specific segments of
patient populations.

Sources of funding

4.1. Limitations

The abstract was presented in the form of a poster at the annual
scientific sessions of the American College of Cardiology 2021.

No specific funding was associated with this research.
Disclosures

Several limitations must be acknowledged. Adherence measures
used here were highly objective and relied mainly on medical charts and
data collected from pharmacy records without subjective confirmation
of adherence. A pharmacy refill does not necessarily imply that patients
took all scheduled doses on time, known as medication compliance. Six
(5.1%) patients had missing racial data. Other critiques include a small
sample size of 144 patients within a single center study, with low power,
which may limit applicability to the generalized population, difficulty in
calculating PDC for warfarin due to frequent dosing changes based on
INR, and variability in the quality of each individual calculated PDC (i.
e., some patients had data for a few months whereas others had data
over multiple years). There may also be unmeasured confounders, which
could have influenced our findings.
Prior studies have demonstrated that African American patients have
a higher mortality after PE compared to White patients [27]. Improving
anticoagulant adherence in this specific patient population is crucial.
Further studies are needed to address the factors leading to reduced
adherence in African American and minority races.

Declaration of competing interest
The authors declare that they have no known competing financial
interests or personal relationships that could have appeared to influence
the work reported in this paper.
Acknowledgment
Pulmonary Embolism Response Team members, Loyola University
Medical Center.
Appendix A. Supplementary data
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.tru.2022.100100.
References

5. Conclusions

[1] B. Rivera-Lebron, M. McDaniel, K. Ahrar, et al., Diagnosis, treatment and follow up
of acute pulmonary embolism: consensus practice from the PERT consortium, Clin.
Appl. Thromb. Hemost. 25 (2019), https://doi.org/10.1177/1076029619853037,
1076029619853037.
[2] CDC. Data and Statistics on Venous Thromboembolism. https://www.cdc.gov/n
cbddd/dvt/data.html. Published February 12, 2020. Accessed July 27, 2021.
[3] Acute management of pulmonary embolism - American college of cardiology. htt
ps://www.acc.org/latest-in-cardiology/articles/2017/10/23/12/12/acute-man
agement-of-pulmonary-embolism. Accessed July 27, 2021.
[4] F.A. Klok, D.M. Cohn, S. Middeldorp, et al., Quality of life after pulmonary
embolism: validation of the PEmb-QoL Questionnaire, J. Thromb. Haemostasis 8
(3) (2010) 523–532, https://doi.org/10.1111/j.1538-7836.2009.03726.x.

In our study, a racial disparity exists in anticoagulation adherence
after an acute PE. African American patients and other minority races
had lower adherence compared to White patients. Further studies are
needed to address underlying contributors and get the opportunities to
improve adherence in this population.

5

K. Merchant et al.

Thrombosis Update 6 (2022) 100100
[16] H.B. Bosworth, B. Powers, J.M. Grubber, et al., Racial differences in blood pressure
control: potential explanatory factors, J. Gen. Intern. Med. 23 (5) (2008) 692–698,
https://doi.org/10.1007/s11606-008-0547-7.
[17] L.T. Clark, K.C. Maki, R. Galant, D.J. Maron, T.A. Pearson, M.H. Davidson, Ethnic
differences in achievement of cholesterol treatment goals. Results from the
national cholesterol education program evaluation project utilizing novel Etechnology II, J. Gen. Intern. Med. 21 (4) (2006) 320–326, https://doi.org/
10.1111/j.1525-1497.2006.00349.x.
[18] W.F. Gellad, J.S. Haas, D.G. Safran, Race/ethnicity and nonadherence to
prescription medications among seniors: results of a national study, J. Gen. Intern.
Med. 22 (11) (2007) 1572–1578, https://doi.org/10.1007/s11606-007-0385-z.
[19] J.M. Schectman, M.M. Nadkarni, J.D. Voss, The association between diabetes
metabolic control and drug adherence in an indigent population, Diabetes Care 25
(6) (2002) 1015–1021, https://doi.org/10.2337/diacare.25.6.1015.
[20] B.S. Gerber, Y.I. Cho, A.M. Arozullah, S.-Y.D. Lee, Racial differences in medication
adherence: a cross-sectional study of Medicare enrollees, Am. J. Geriatr.
Pharmacother. 8 (2) (2010) 136–145, https://doi.org/10.1016/j.
amjopharm.2010.03.002.
[21] R.C. Kaplan, N.C. Bhalodkar, E.J. Brown, J. White, D.L. Brown, Race, ethnicity, and
sociocultural characteristics predict noncompliance with lipid-lowering
medications, Prev. Med. 39 (6) (2004) 1249–1255, https://doi.org/10.1016/j.
ypmed.2004.04.041.
[22] J.E. Aikens, J.D. Piette, Diabetic patients’ medication underuse, illness outcomes,
and beliefs about antihyperglycemic and antihypertensive treatments, Diabetes
Care 32 (1) (2009) 19–24, https://doi.org/10.2337/dc08-1533.
[23] E.S. Huang, S.E.S. Brown, N. Thakur, et al., Racial/ethnic differences in concerns
about current and future medications among patients with type 2 diabetes,
Diabetes Care 32 (2) (2009) 311–316, https://doi.org/10.2337/dc08-1307.
[24] D.J. Gaskin, B.A. Briesacher, R. Limcangco, B.L. Brigantti, Exploring racial and
ethnic disparities in prescription drug spending and use among Medicare
beneficiaries, Am. J. Geriatr. Pharmacother. 4 (2) (2006) 96–111, https://doi.org/
10.1016/j.amjopharm.2006.06.008.
[25] D. Barcellona, P. Contu, F. Marongiu, Patient education and oral anticoagulant
therapy, Haematologica 87 (10) (2002) 1081–1086, https://doi.org/10.1016/J.
PEC.2007.08.010.
[26] K.M. Mazor, J. Baril, E. Dugan, F. Spencer, P. Burgwinkle, J.H. Gurwitz, Patient
education about anticoagulant medication: is narrative evidence or statistical
evidence more effective? Patient Educ. Counsel. 69 (1–3) (2007) 145–157, https://
doi.org/10.1016/j.pec.2007.08.010.
[27] S.A. Ibrahim, R.A. Stone, D.S. Obrosky, J. Sartorius, M.J. Fine, D. Aujesky, Racial
differences in 30-day mortality for pulmonary embolism, Am. J. Publ. Health 96
(12) (2006) 2161–2164, https://doi.org/10.2105/AJPH.2005.078618.

[5] M.A. Maturana, M.P. Seitz, I. Pour-Ghaz, U.N. Ibebuogu, R.N. Khouzam, Invasive
strategies for the treatment of pulmonary embolism. Where are we in 2020? Curr.
Probl. Cardiol. 46 (3) (2021) 100650, https://doi.org/10.1016/j.
cpcardiol.2020.100650.
[6] C. Kearon, W. Ageno, S.C. Cannegieter, et al., Categorization of patients as having
provoked or unprovoked venous thromboembolism: guidance from the SSC of
ISTH, J. Thromb. Haemostasis 14 (7) (2016) 1480–1483, https://doi.org/10.1111/
jth.13336.
[7] L. Cart, G. Serzian, S. Humbert, et al., Clinical patterns and significance of noncompliance with guideline-recommended treatment of acute pulmonary embolism,
Arch. Cardiovasc. Dis. 113 (1) (2020) 31–39, https://doi.org/10.1016/j.
acvd.2019.09.009.
[8] A.C. Spyropoulos, R. Preblick, W.J. Kwong, M. Lingohr-Smith, J. Lin, Is adherence
to the American College of chest physicians recommended anticoagulation
treatment duration associated with different outcomes among patients with venous
thromboembolism? Clin. Appl. Thromb. Hemost. 23 (6) (2017) 532–541, https://
doi.org/10.1177/1076029616680475.
[9] R.S. Rokosh, J.H. Grazi, D. Ruohoniemi, et al., High incidence of patients lost to
follow-up after venous thromboembolism diagnosis - identifying an unmet need for
targeted transition of care, Vascular (June 2021), https://doi.org/10.1177/
17085381211020969, 17085381211020968.
[10] S. Kuhrau, D. Masic, E. Mancl, et al., Impact of pulmonary embolism Response
team on anticoagulation prescribing patterns in patients with acute pulmonary
embolism, J. Pharm. Pract. (July 2020), https://doi.org/10.1177/
0897190020940125, 897190020940125.
[11] A.M. Peterson, D.P. Nau, J.A. Cramer, J. Benner, F. Gwadry-Sridhar, M. Nichol,
A checklist for medication compliance and persistence studies using retrospective
databases, Value Health 10 (1) (2007) 3–12, https://doi.org/10.1111/j.15244733.2006.00139.x.
[12] S.L. Canfield, A. Zuckerman, R.H. Anguiano, et al., Navigating the wild west of
medication adherence reporting in specialty pharmacy, J. Manag. Care Spec.
Pharm. 25 (10) (2019) 1073–1077, https://doi.org/10.18553/
jmcp.2019.25.10.1073.
[13] M. Viswanathan, C.E. Golin, C.D. Jones, et al., Interventions to improve adherence
to self-administered medications for chronic diseases in the United States: a
systematic review, Ann. Intern. Med. 157 (11) (2012) 785–795, https://doi.org/
10.7326/0003-4819-157-11-201212040-00538.
[14] S.R. Reading, M.H. Black, D.E. Singer, et al., Risk factors for medication nonadherence among atrial fibrillation patients, BMC Cardiovasc. Disord. 19 (1)
(2019) 38, https://doi.org/10.1186/s12872-019-1019-1.
[15] A. Pacleb, N. Lowres, S. Randall, L. Neubeck, R. Gallagher, Adherence to cardiac
medications in patients with atrial fibrillation: a pilot study, Heart Lung Circ. 29
(7) (2020) e131–e139, https://doi.org/10.1016/j.hlc.2019.11.012.

6

